These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10915071)

  • 1. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
    Atkinson B; Isaacson J; Knowles M; Mazabel E; Patick AK
    J Infect Dis; 2000 Aug; 182(2):420-7. PubMed ID: 10915071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
    Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens.
    Fitzgibbon JE; Gaur S; Walsman SM; Janahi M; Whitley-Williams P; John JF
    AIDS Res Hum Retroviruses; 2001 Sep; 17(14):1321-8. PubMed ID: 11602042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M;
    Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
    Ferrer E; Podzamczer D; Arnedo M; Fumero E; McKenna P; Rinehart A; Pérez JL; Barberá MJ; Pumarola T; Gatell JM; Gudiol F;
    J Infect Dis; 2003 Feb; 187(4):687-90. PubMed ID: 12599088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
    Moolasart P; Likanonsakul S
    Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):280-7. PubMed ID: 12236426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
    J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
    Goodgame JC; Pottage JC; Jablonowski H; Hardy WD; Stein A; Fischl M; Morrow P; Feinberg J; Brothers CH; Vafidis I; Nacci P; Yeo J; Pedneault L
    Antivir Ther; 2000 Sep; 5(3):215-25. PubMed ID: 11075942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
    Jankelevich S; Mueller BU; Mackall CL; Smith S; Zwerski S; Wood LV; Zeichner SL; Serchuck L; Steinberg SM; Nelson RP; Sleasman JW; Nguyen BY; Pizzo PA; Yarchoan R
    J Infect Dis; 2001 Apr; 183(7):1116-20. PubMed ID: 11237839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of 2 years of treatment with protease-inhibitor--containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1.
    van Rossum AM; Geelen SP; Hartwig NG; Wolfs TF; Weemaes CM; Scherpbier HJ; van Lochem EG; Hop WC; Schutten M; Osterhaus AD; Burger DM; de Groot R
    Clin Infect Dis; 2002 Apr; 34(7):1008-16. PubMed ID: 11880968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial.
    Pillay D; Walker AS; Gibb DM; de Rossi A; Kaye S; Ait-Khaled M; Muñoz-Fernandez M; Babiker A
    J Infect Dis; 2002 Sep; 186(5):617-25. PubMed ID: 12195348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.
    Rabaud C; Bevilacqua S; Beguinot I; Dorvaux V; Schuhmacher H; May T; Canton P
    Clin Infect Dis; 2001 May; 32(10):1494-5. PubMed ID: 11317252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
    Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.